February 10, 2023 03:30 PM EST

Bristol Myers, 2seventy roll out full Abecma data in earlier-stage cancer

Paul Schloesser

Associate Editor

Bristol Myers Squibb and 2seventy bio teased a top-line win for their BCMA-targeting CAR-T Abecma in earlier stages of multiple myeloma back in August. Now …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Bristol Myers, 2seventy roll out full Abecma data in earlier-stage cancer

Paul Schloesser

Associate Editor

Sign up to read this article for free.

Sr. Manager/Associate Director, Document Control

Viridian Therapeutics

Waltham, MA, USA

You bet your life: After I was diagnosed with a rare cancer, I discovered how a small band of physician-scientists ...

Why did Eli Lilly ask a patient on a compounded GLP-1 drug for their medical information?

Nura Bio raises $68M for clinical tests of SARM1 inhibitor to potentially slow or prevent nerve degeneration

Roche outlines commercial manufacturing strategy for GLP-1/GIP assets

A VC-backed genetic testing startup to 'consider' making an offer to buy 23andMe

Breaking down silos with a new quantitative approach to drug development

Bris­tol My­ers, 2sev­en­ty roll out full Abec­ma da­ta in ear­li­er-stage can­cer

Associate Editor

Sign up to read this article for free.

Viridian Therapeutics

Waltham, MA, USA

Bristol Myers, 2seventy roll out full Abecma data in earlier-stage cancer